BENSERAZIDE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C10H15N3O5
Molecular Weight	257.2432
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC(CO)C(=O)NNCC1=C(O)C(O)=C(O)C=C1

InChI

InChIKey=BNQDCRGUHNALGH-UHFFFAOYSA-N

InChI=1S/C10H15N3O5/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16/h1-2,6,12,14-17H,3-4,11H2,(H,13,18)

HIDE SMILES / InChI

Molecular Formula	C10H15N3O5
Molecular Weight	257.2432
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.medicines.org.uk/emc/PIL.3212.latest.pdf | http://medsafe.govt.nz/profs/Datasheet/m/Madoparcapdisptab.pdf | https://www.ncbi.nlm.nih.gov/pubmed/3322836

Benserazide is a peripherally-acting aromatic L-amino acid decarboxylase (AADC) or DOPA decarboxylase inhibitor. Benserazide is only used in conjunction with L-dopa for the treatment of Parkinson's disease under the brand name Madopar in the UK. Madopar HBS (125 mg) is a controlled-release dosage form with 100 mg L-dopa and 25 mg benserazide.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DOPA decarboxylase 15 Target ID: CHEMBL1843 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2289048 \| https://www.ncbi.nlm.nih.gov/pubmed/22384042	Inhibitor 8504		550.0 nM [IC50]
Cystathionine beta-synthase 2 Target ID: CHEMBL3399911 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27521834	Inhibitor 8504		30.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Parkinson's disease 232 Sources: http://medsafe.govt.nz/profs/Datasheet/m/Madoparcapdisptab.pdf	Primary		Approved 8583	MADOPAR Approved Use MADOPAR is indicated for the treatment of all forms of Parkinson's syndrome with the exception of medicine-induced parkinsonism.

C_max

Value	Dose	Co-administered	Analyte	Population
620.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31378952/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: LEVODOPA	LEVODOPA	LEVODOPA plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED
627.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31378952/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: LEVODOPA	LEVODOPA	LEVODOPA plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED
0.287 μM EXPERIMENT https://onlinelibrary.wiley.com/doi/epdf/10.1111/ncn3.152	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: LEVODOPA	LEVODOPA	BENSERAZIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
8.37 μM EXPERIMENT https://onlinelibrary.wiley.com/doi/epdf/10.1111/ncn3.152	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: LEVODOPA	LEVODOPA	LEVODOPA plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10053234/	25 mg 3 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: LEVODOPA	LEVODOPA	BENSERAZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10053234/	50 mg 3 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered: LEVODOPA	LEVODOPA	BENSERAZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10053234/	50 mg 3 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered: LEVODOPA	LEVODOPA	BENSERAZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
2784.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31378952/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: LEVODOPA	LEVODOPA	LEVODOPA plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED
2753.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31378952/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: LEVODOPA	LEVODOPA	LEVODOPA plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED
511 μM × h EXPERIMENT https://onlinelibrary.wiley.com/doi/epdf/10.1111/ncn3.152	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: LEVODOPA	LEVODOPA	LEVODOPA plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10053234/	25 mg 3 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: LEVODOPA	LEVODOPA	BENSERAZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10053234/	50 mg 3 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered: LEVODOPA	LEVODOPA	BENSERAZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10053234/	50 mg 3 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered: LEVODOPA	LEVODOPA	BENSERAZIDE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.28 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31378952/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: LEVODOPA	LEVODOPA	LEVODOPA plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED
1.79 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31378952/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: LEVODOPA	LEVODOPA	LEVODOPA plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED
48.6 min EXPERIMENT https://onlinelibrary.wiley.com/doi/epdf/10.1111/ncn3.152	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: LEVODOPA	LEVODOPA	BENSERAZIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
72 min EXPERIMENT https://onlinelibrary.wiley.com/doi/epdf/10.1111/ncn3.152	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: LEVODOPA	LEVODOPA	LEVODOPA plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1266576/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1266576/	Disc. AE: Anxiety, Restlessness... Other AEs: Vomiting... AEs leading to discontinuation/dose reduction: Anxiety (2.2%) Restlessness (2.2%) Sleepiness (2.2%) Nausea (4.4%) Confusion (2.2%) Hallucinations (2.2%) Other AEs: Vomiting (4.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/1266576/
200 mg 3 times / day multiple, oral Highest studied dose Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/9241095/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/9241095/	Sources: https://pubmed.ncbi.nlm.nih.gov/9241095/

AEs

AE	Significance	Dose	Population
Anxiety	2.2% Disc. AE	200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1266576/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1266576/
Confusion	2.2% Disc. AE	200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1266576/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1266576/
Hallucinations	2.2% Disc. AE	200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1266576/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1266576/
Restlessness	2.2% Disc. AE	200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1266576/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1266576/
Sleepiness	2.2% Disc. AE	200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1266576/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1266576/
Vomiting	4.4%	200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1266576/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1266576/
Nausea	4.4% Disc. AE	200 mg 1 times / day multiple, oral Highest studied dose Dose: 200 mg, 1 times / day Route: oral Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1266576/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/1266576/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
BSEP 550 OATP1B1 1079 OATP1B3 961	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
BSEP 554	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw2MDIwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEwOTY5NzkifX0=	weak [IC50 116.6 uM]
OATP1B1 1095	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyNTU3NzgifX0=	yes [Inhibition 10 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEyNTU3NzgifX0=	yes [Inhibition 10 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/2327#section=BioAssay-Results Page: 87 \| 90	no

PubMed

Title	Date	PubMed
Paraphilic behaviours in a parkinsonian patient with hedonistic homeostatic dysregulation.	2006-12	16454868
Levodopa availability improves with progression of Parkinson's disease.	2006-09	16649094
Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine.	2006-06	16531050
L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase.	2006-06	16504219
Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: effects of subthalamotomy and levodopa treatment.	2006-04-21	16574080
Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.	2006-01	16127720
Effect of L-dopa decarboxylase inhibitor benserazide on renal function in streptozotocin-diabetic rats.	2006	16636577
A spectroscopic study on applicability of spectral analysis for simultaneous quantification of l-dopa, benserazide and ascorbic acid in batch and flow systems.	2005-11	16257716
Impact of levodopa on reduced nerve growth factor levels in patients with Parkinson disease.	2005-10-22	16239764
Uptake and decarboxylation of L-3,4-dihydroxyphenylalanine in cultured monkey placenta amniotic epithelial cells.	2005-09-06	16580727
Enhanced cortical dopamine output and antipsychotic-like effect of raclopride with adjunctive low-dose L-dopa.	2005-08-15	16102547
[Idiopathic Parkinson's disease: practical hints for the treatment].	2005-07-27	16117469
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.	2005-07	15899244
Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.	2005-06	15747357
Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.	2005-04	15875340
Localized pemphigoid on the soles of both feet.	2005-04	15811084
Cross talk between the intrarenal dopaminergic and cyclooxygenase-2 systems.	2005-04	15613619
Cholinopositive effect of dilept (neurotensin peptidomimetic) as the basis of its mnemotropic effect.	2005-03	16027848
DOPA-sensitive dystonia-plus syndrome.	2005-03	15739726
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.	2005-03	15698633
3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease.	2005-02-23	15728853
[Madopar in the complex therapy of ischemic insult].	2005-01	15754768
[Six months treatment of restless legs syndrome with levodopa/benserazide in domiciliary practice].	2004-12-09	15662897
Simultaneous determination of levodopa and benserazide by stopped-flow injection analysis and three-way multivariate calibration of kinetic-spectrophotometric data.	2004-11-15	15522528
[What helps in the treatment of restless legs?].	2004-11-11	15600046
L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.	2004-08-31	15265640
Influence of dipeptidyl peptidase inhibitors on growth, peptidase activity, and ammonia production by ruminal microorganisms.	2004-08	15297916
Antinociceptive mechanism of L-DOPA.	2004-07	15275774
Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease.	2004-06-17	15182961
The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.	2004-05-05	15084427
Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid.	2004-05	15164191
Parkinsonism following anterior choroidal artery stroke.	2004-04	15061831
Comparison between dopaminergic agents and physical exercise as treatment for periodic limb movements in patients with spinal cord injury.	2004-04	15060518
Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome.	2004-04	14985260
Augmentation of endogenous dopamine production increases lung liquid clearance.	2004-03-15	14701706
Phenotypic heterogeneity of dopa-responsive dystonia in monozygotic twins.	2004-02-24	14981186
Effect of the adenosine A2A receptor antagonist 8-(3-chlorostyryl)caffeine on L-DOPA biotransformation in rat striatum.	2004-02-20	14751592
[Influence of L-DOPA on rat brain depending on individual behavioral features].	2004	15849866
Depletion and restoration of endogenous monoamines affects beta-CIT binding to serotonin but not dopamine transporters in non-human primates.	2004	15354387
Gas chromatography/mass spectrometric identification of dopaminergic metabolites in striata of rats treated with L-DOPA.	2004	14978802
Improvement of sleep hypopnea by antiparkinsonian drugs in a patient with Parkinson's disease: a polysomnographic study.	2003-11	14686757
Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide.	2003-11	14517707
Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?	2003-10	14598082
One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?	2003-10	14534925
Hyperleptinemia elicited by the 5-HT precursor, 5-hydroxytryptophan in mice: involvement of insulin.	2003-09-19	12941435
Effect of acute and chronic administration of U50,488, a kappa opioid receptor agonist, in 6-OHDA-lesioned rats chronically treated with levodopa.	2003-09	12957489
Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).	2003-06	12787259
[The effect of shourong compound formula on levels of dopamine and its metabolites in brain of Parkinson's disease mice induced by reserpine].	2002-05	12774329
A case report of dopa-responsive dystonia.	2001-06	12901504
Effects of brain serotonin alterations on prostaglandin E1-induced bradycardia in rats.	1979-02	153969

Patents

Sample Use Guides

In Vivo Use Guide

Patients NOT already treated with levodopa: The usual starting dose is one 50 mg/12.5 mg tablet (50 mg levodopa), three or four times a day. Your doctor will then increase your dose every 2 to 3 days until they find the right dose for you. Patients already treated with levodopa: Your starting dose of Madopar will be one less 100 mg/25 mg tablet than the number of levodopa 500 mg capsules or tablets you take each day. For example if you take four levodopa tablets (2000 mg levodopa) each day, your doctor will start by giving you three Madopar 100 mg/25 mg tablets daily. After one week your doctor may then start to increase your dose every 2 to 3 days until they find the right dose for you. Patients already treated with a combined levodopa/decarboxylase inhibitor: The usual starting dose is one 50 mg/12.5 mg tablet (50 mg levodopa), three or four times a day. Your doctor will then increase your dose every 2 to 3 days until they find the right dose for you.

Route of Administration: Oral

In Vitro Use Guide

Benserazide inhibited AADC with IC50 550 and 530 nM in the presence and absence of 1 mM pargyline, respectively.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:56:07 GMT 2025` Edited by `admin` on `Wed Apr 02 08:56:07 GMT 2025`
Record UNII	762OS3ZEJU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BENSERAZIDE

Official Name

English

MADOPAR COMPONENT BENSERAZIDE

Preferred Name

English

BENSERAZIDE [USAN]

Common Name

English

DL-SERINE, 2-((2,3,4-TRIHYDROXYPHENYL)METHYL)HYDRAZIDE

Common Name

English

RO 4-4602

Code

English

Benserazide [WHO-DD]

Common Name

English

BENSERAZIDE [MART.]

Common Name

English

BENSERAZIDE [MI]

Common Name

English

PROLOPA COMPONENT BENSERAZIDE

Brand Name

English

DL-SERINE 2-(2,3,4-TRIHYDROXYBENZYL)HYDRAZIDE

Common Name

English

benserazide [INN]

Common Name

English

RO-4-4602

Code

English

SERAZIDE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C38149